Abstract
Despite the fact that intracerebral hemorrhage (ICH) is the deadliest and least treatable of all stroke subtypes, historically researchers have directed most of their efforts toward ischemic strokes. However in the past few years this tendency has been changing, and several studies are showing very interesting results that allow us to believe that in the following years ICH management will change dramatically, paralleling the recent revolution that ischemic stroke treatment experienced in the past decade. Studies offering a better understanding of risk factors, pathophysiology, and treatment will help in primary and secondary prevention and also in developing therapeutic strategies to reduce brain damage. This review comments on some of the most relevant publications during the past year in any field related to ICH.
Similar content being viewed by others
References and Recommended Reading
Priorities for clinical research in intracerebral hemorrhage: report from a national institute of neurological disorders and stroke workshop. Stroke 2005, 36:e23–e41.
Feldmann E, Broderick JP, Kernan WN, et al.: Major risk factors for intracerebral hemorrhage in the young are modifiable. Stroke 2005, 36:1881–1885.
Kim HC, Kang DR, Nam CM, et al.: Elevated serum aminotransferase level as a predictor of intracerebral hemorrhage: Korea medical insurance corporation study. Stroke 2005, 36:1642–1647.
Van Guelpen B, Hultdin J, Johansson I, et al.: Folate, vitamin B12, and risk of ischemic and hemorrhagic stroke: a prospective, nested case-referent study of plasma concentrations and dietary intake. Stroke 2005, 36:1426–1431.
Woo D, Kaushal R, Chakraborty R, et al.: Association of apolipoprotein e4 and haplotypes of the apolipoprotein e gene with lobar intracerebral hemorrhage. Stroke 2005, 36:1874–1879.
Passero SG, Calchetti B, Bartalini S: Intracranial bleeding in patients with vertebrobasilar dolichoectasia. Stroke 2005, 36:1421–1425.
Brott T, Broderick J, Kothari R, et al.: Early hemorrhage growth in patients with intracerebral hemorrhage. Stroke 1997, 28:1–5.
Fuji Y, Takeuchi S, Sasaki O, et al.: Multivariate analysis of predictors of hematoma enlargement in spontaneous intracerebral hemorrhage. Stroke 1998, 29:1160–1166.
Fujitsu K, Muramoto M, Ikeda Y, et al.: Indications for surgical treatment of putaminal hemorrhage. Comparative study based on serial CT and time-course analysis. J Neurosurg 1990, 73:518–525.
Kazui S, Naritomi H, Yamamoto H, et al.: Enlargement of spontaneous intracerebral hemorrhage. Incidence and time course. Stroke 1996, 27:1783–1787.
Silva Y, Leira R, Tejada J, et al.: Molecular signatures of vascular injury are associated with early growth of intracerebral hemorrhage. Stroke 2005, 36:86–91.
Orakcioglu B, Fiebach JB, Steiner T, et al.: Evolution of early perihemorrhagic changes—ischemia vs. Edema: an MRI study in rats. Exp Neurol 2005, 193:369–376.
Huang FP, Xi G, Keep RF, et al.: Brain edema after experimental intracerebral hemorrhage: role of hemoglobin degradation products. J Neurosurg 2002, 96:287–293.
Chiueh CC: Iron overload, oxidative stress, and axonal dystrophy in brain disorders. Pediatr Neurol 2001, 25:138–147.
Shao J, Xi G, Hua Y, et al.: Intracerebral hemorrhage in the iron-deficient rat. Stroke 2005, 36:660–664.
Nakamura T, Xi G, Park JW, et al.: Holo-transferrin and thrombin can interact to cause brain damage. Stroke 2005, 36:348–352.
Nagatsuna T, Nomura S, Suehiro E, et al.: Systemic administration of argatroban reduces secondary brain damage in a rat model of intracerebral hemorrhage: histopathological assessment. Cerebrovasc Dis 2005, 19:192–200.
Abilleira S, Montaner J, Molina CA, et al.: Matrix metalloproteinase-9 concentration after spontaneous intracerebral hemorrhage. J Neurosurg 2003, 99:65–70.
Alvarez-Sabin J, Delgado P, Abilleira S, et al.: Temporal profile of matrix metalloproteinases and their inhibitors after spontaneous intracerebral hemorrhage: Relationship to clinical and radiological outcome. Stroke 2004, 35:1316–1322. MMPs constitute a fascinating field in ischemic and hemorrhagic stroke, and therapeutic approaches involving MMPs will certainly be developed in the following years.
Lee JM, Yin K, Hsin I, et al.: Matrix metalloproteinase-9 in cerebral-amyloid-angiopathy-related hemorrhage. J Neurol Sci 2005, 230:249–254.
Wang J, Tsirka SE: Neuroprotection by inhibition of matrix metalloproteinases in a mouse model of intracerebral haemorrhage. Brain 2005, 128:1622–1633.
Ritter MA, Droste DW, Hegedus K, et al.: Role of cerebral amyloid angiopathy in intracerebral hemorrhage in hypertensive patients. Neurology 2005, 64:1233–1237.
Lu A, Tang Y, Ran R, et al.: Brain genomics of intracerebral hemorrhage. J Cereb Blood Flow Metab 2005, In press. This is a novel study that in a very elegant way will help identify new therapeutic approaches for ICH.
Mendelow AD, Gregson BA, Fernandes HM, et al.: Early surgery versus initial conservative treatment in patients with spontaneous supratentorial intracerebral haematomas in the international surgical trial in intracerebral haemorrhage (STICH): a randomised trial. Lancet 2005, 365:387–397. This is the first adequately powered randomized trial of open craniotomy and elective clot evacuation versus nonsurgical management. It confirmed the lack of clinical benefit of the routine surgical approach.
Nakano T, Ohkuma H: Surgery versus conservative treatment for intracerebral haemorrhage—is there an end to the long controversy? Lancet 2005, 365:361–362.
Mayer SA, Brun NC, Begtrup K, et al.: Recombinant activated factor vii for acute intracerebral hemorrhage. N Engl J Med 2005, 352:777–785. This was first controlled study to show the benefit of any therapy for ICH. It was a confirmatory study that found the best dosage and has already started exciting developments for the entire stroke field
Qureshi AI, Mohammad YM, Yahia AM, et al.: A prospective multicenter study to evaluate the feasibility and safety of aggressive antihypertensive treatment in patients with acute intracerebral hemorrhage. J Intensive Care Med 2005, 20:34–42.
Misra UK, Kalita J, Ranjan P, Mandal SK: Mannitol in intracerebral hemorrhage: A randomized controlled study. J Neurol Sci 2005, 234:41–45.
Belayev L, Saul I, Busto R, et al.: Albumin treatment reduces neurological deficit and protects blood-brain barrier integrity after acute intracortical hematoma in the rat. Stroke 2005, 36:326–331.
Lee ST, Chu K, Jung KH, et al.: Memantine reduces hematoma expansion in experimental intracerebral hemorrhage, resulting in functional improvement. J Cereb Blood Flow Metab 2005, In press.
Wang J, Tsirka SE: Tuftsin fragment 1–3 is beneficial when delivered after the induction of intracerebral hemorrhage. Stroke 2005, 36:613–618.
Nan Z, Grande A, Sanberg CD, et al.: Infusion of human umbilical cord blood ameliorates neurologic deficits in rats with hemorrhagic brain injury. Ann N Y Acad Sci 2005, 1049:84–96.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Ribo, M., Grotta, J.C. Latest advances in intracerebral hemorrhage. Curr Neurol Neurosci Rep 6, 17–22 (2006). https://doi.org/10.1007/s11910-996-0004-0
Issue Date:
DOI: https://doi.org/10.1007/s11910-996-0004-0